The latest price target for Design Therapeutics (NASDAQ:DSGN) was reported by RBC Capital on August 6, 2024. The analyst firm set a price target for $4.00 expecting DSGN to fall to within 12 months (a possible -35.59% downside). 4 analyst firms have reported ratings in the last year.

The latest analyst rating for Design Therapeutics (NASDAQ:DSGN) was provided by RBC Capital, and Design Therapeutics reiterated their sector perform rating.

The last upgrade for Design Therapeutics Inc happened on May 7, 2024 when Piper Sandler raised their price target to $12. Piper Sandler previously had a neutral for Design Therapeutics Inc.

The last downgrade for Design Therapeutics Inc happened on August 15, 2023 when Wedbush changed their price target from N/A to $6 for Design Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Design Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Design Therapeutics was filed on August 6, 2024 so you should expect the next rating to be made available sometime around August 6, 2025.

While ratings are subjective and will change, the latest Design Therapeutics (DSGN) rating was a reiterated with a price target of $4.00 to $4.00. The current price Design Therapeutics (DSGN) is trading at is $6.21, which is out of the analyst’s predicted range.